Novel Targeted Therapy, Immunotherapy, and Immune Biomarkers for Gastroesophageal and Liver Cancer

A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Gastrointestinal Oncology".

Deadline for manuscript submissions: 30 June 2024 | Viewed by 2671

Special Issue Editors


E-Mail Website
Guest Editor
Department of Medicine, Division of Hematology and Oncology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Interests: gastric cancer; esophageal cancer; colon cancer; hepatocellular carcinoma; bile duct cancer
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Medical Oncology, Novant Health Cancer Institute, Charlotte, NC 28204, USA
Interests: developmental therapeutics; molecularly targeted agents; epigenetic modifiers; small molecule inhibitors; immune-oncology; bispecifics; T-cell engagers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Targeted therapy for cancer involves inhibiting tumor growth by disrupting essential chemical pathways or mutant proteins. Conversely, immunotherapy aims to provoke a host immune response, culminating in tumor destruction. These strategies manifest heightened efficacy within specific subsets of gastroesophageal cancer patients.

Gastroesophageal cancer, encompassing gastric and esophageal carcinomas along with gastroesophageal junction carcinoma, is a prevalent malignancy in the gastrointestinal realm. It ranks fourth and fifth globally in terms of incidence and mortality, respectively. Hepatocellular carcinoma (HCC) is one of the most common and lethal hepatic malignancies. The development of personalized regimens, including vaccine therapies and adoptive cell treatments, coupled with an intricate comprehension of immune response predictive biomarkers, holds promise for optimizing therapeutic outcomes.

This Special Issue is dedicated to shedding light on therapeutic advances for gastroesophageal cancer and HCC. It will encompass insights into novel standard and investigational treatment interventions involving targeted therapy and immunotherapy in this population. The emphasis is on research work highlighting or investigating potential prognostic and therapeutic predictive biomarkers of those novel therapeutics.

You may choose our Joint Special Issue in Cancers.

Dr. Anwaar Saeed
Dr. Ludimila Cavalcante
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • immunotherapy
  • targeted therapy
  • immune checkpoint inhibitors
  • gastroesophageal cancer
  • liver cancer
  • biomarkers

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

13 pages, 275 KiB  
Review
Combining Immune Checkpoint Inhibitors with Loco-Regional Treatments in Hepatocellular Carcinoma: Ready for Prime Time?
by Juliette Boilève, Valentine Guimas, Arthur David, Clément Bailly and Yann Touchefeu
Curr. Oncol. 2024, 31(6), 3199-3211; https://doi.org/10.3390/curroncol31060242 - 31 May 2024
Viewed by 299
Abstract
Hepatocellular carcinoma (HCC) is a disease with a poor prognosis, often diagnosed at an advanced stage. Therapeutic options have developed considerably in recent years, particularly with trans-arterial treatments. Systemic treatments have also evolved significantly, with the rise of immune checkpoint inhibitors (ICI) as [...] Read more.
Hepatocellular carcinoma (HCC) is a disease with a poor prognosis, often diagnosed at an advanced stage. Therapeutic options have developed considerably in recent years, particularly with trans-arterial treatments. Systemic treatments have also evolved significantly, with the rise of immune checkpoint inhibitors (ICI) as first-line treatment for advanced HCC. The combination of loco-regional treatments and ICI is opening up new prospects and is the subject of numerous clinical trials. Recently, two global phase 3 trials investigating ICI-based adjuvant combinations have demonstrated improvements in recurrence-free survival or progression-free survival in patients treated with resection, ablation, or trans-arterial chemoembolization. However, mature data and overall survival results are still awaited but will be difficult to interpret. We are at the start of a new era of combinations of loco-regional treatments and immunotherapy. The identification of the best therapeutic strategies and predictive biomarkers is a crucial issue for future standards in clinical practice. Full article
13 pages, 309 KiB  
Review
Current and Emerging Role of Monoclonal Antibody-Based First-Line Treatment in Advanced Gastro-Esophageal and Gastric Cancer
by Audrey Désilets, Reem Elkhoury, Ahmad Gebai and Mustapha Tehfe
Curr. Oncol. 2023, 30(10), 9304-9316; https://doi.org/10.3390/curroncol30100672 - 20 Oct 2023
Cited by 1 | Viewed by 1962
Abstract
Gastric cancer is the fifth most common malignancy worldwide and one of the main causes of cancer-related death. While surgical treatment is the only curative option for early disease, many have inoperable or advanced disease at diagnosis. Treatment in this case would be [...] Read more.
Gastric cancer is the fifth most common malignancy worldwide and one of the main causes of cancer-related death. While surgical treatment is the only curative option for early disease, many have inoperable or advanced disease at diagnosis. Treatment in this case would be a combination of chemotherapy and immunotherapy. Gastro-esophageal (GEJ) and gastric cancer (GC) genetic profiling with current molecular diagnostic techniques has significantly changed the therapeutic landscape in advanced cancers. The identification of key players in GEJ and GC survival and proliferation, such as human epidermal growth factor 2 (HER2), vascular endothelial growth factor (VEGF), and programmed cell death protein 1 (PD-1)/programmed cell death ligand-1 (PD-L1), has allowed for the individualization of advanced cancer treatment and significant improvement in overall survival and progression-free survival of patients. This review comprehensively examines the current and emerging role of monoclonal antibody-based first-line treatments in advanced GEJ and GC. We explore the impact of monoclonal antibodies targeting HER2, VEGF, PD-1/PD-L1, and Claudin 18.2 (CLDN18.2) on the first-line treatment landscape by talking about key clinical trials. This review emphasizes the importance of biomarker testing for optimal treatment selection and provides practical recommendations based on ASCO guidelines. Full article
Back to TopTop